M&A Deal Summary

Aerie Acquires Avizorex Pharma SL

On November 18, 2019, Aerie acquired life science company Avizorex Pharma SL for 10M USD

Acquisition Highlights
  • This is Aerie’s 1st transaction in the Life Science sector.
  • This is Aerie’s largest (disclosed) transaction.
  • This is Aerie’s 1st transaction in Spain.

M&A Deal Summary
Date 2019-11-18
Target Avizorex Pharma SL
Sector Life Science
Buyer(s) Aerie
Deal Type Add-on Acquisition
Deal Value 10M USD

Target

Avizorex Pharma SL

Barcelona, Spain
Avizorex Pharma SL is an ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. Avizorex Pharma was founded in 2013 and is based in Barcelona, Spain.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aerie

Durham, North Carolina, United States
Category Company
Founded 2005
Sector Life Science
Revenue 194M USD (2021)
DESCRIPTION

Aerie is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie was founded in 2005 and is based in Durham, North Carolina.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Spain) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal